New Therapeutic Strategies in Lupus Nephritis

摘要: Lupus nephritis remains a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). Despite overall advances the clinical management recent decades with earlier recognition disease optimization currently available immunosuppressive regimens, an estimated 10-15% patients progress to end-stage renal (ESRD) requiring dialysis and/or transplantation (Mavragani et al, 2003). Proliferative (International Society Nephrology/Renal Pathology classes III & IV) is most aggressive variant nephritis; figures 1 2 illustrate histology Class IV nephritis.